Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria
Robert A. Brodsky(Johns Hopkins University), Peter Hillmen(Leeds Teaching Hospitals NHS Trust), Antonio M. Risitano(Federico II University Hospital), Hubert Schrezenmeier(German Red Cross), Neal S. Young(National Institutes of Health), Elisabetta Antonioli(University of Florence), Chieh‐Lin Fu(Cleveland Clinic Florida), Henk-André Kroon(Alexion Pharmaceuticals (United States)), Jaroslaw P. Maciejewski(Cleveland Clinic), Carlos de Castro Lozano(Duke Medical Center), Russell P. Rother(Alexion Pharmaceuticals (United States)), Jörg Schubert(Saarland University), Monica Bessler(Memorial Sloan Kettering Cancer Center), Luke Coyle(Royal North Shore Hospital), Anna Gayà(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer)
Cited by 653
Related Papers
HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide
|Biology of Blood and Marrow Transplantation|2008|1.9k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k